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In a previous study we found that testing for four high-risk human
papilloma (HR-HPV) types almost doubled the detection rates of
cervical intraepithelial neoplasia (CIN) 2/3 when added to cervical
cytology in routine screening (Cuzick et al, 1995). In particular,
44% of these lesions occurred in women with negative cytology
and another 23% had only mild or borderline cytological abnor-
malities. The smears were taken by experienced personnel and
several reviews of the smears confirmed the findings. Similar
results have now been reported in other studies (Cox et al, 1995;
Hatch et al, 1995; Walboomers et al, 1995; Ferenczy et al, 1996).
A limitation of these studies is that most women were relatively
young. In our previous study 87% were under 40 years of age. In
general, HPV infection in younger women tends to be at a high
viral load, but often spontaneously regresses, whereas in older
women the virus is more prone to persist, but often the viral load is
lower (Hildesheim et al, 1994; Ho et al, 1995). We now report a
study in women aged 35 or over to evaluate the role of HR-HPV
testing in primary screening of older women. An additional aim
was to evaluate commercially available kits for HPV testing.
PATIENTS AND METHODS
Women aged 35 years and over who were attending for a routine
smear in 40 general practitioner (GP) practices were asked to join
a study in which HPV testing would be performed in addition to
routine cytology. Ethical approval was obtained from the referral
hospital ethics committee (Hammersmith Hospital) and informed
consent was obtained from all participants after a written and oral
explanation of the study was provided by the practice nurse or GP.
A cervical smear was taken using an Aylesbury spatula and put
onto a glass slide in the conventional manner. Remaining material
on the spatula was transferred to narrow tubes by a cotton swab for
polymerase chain reaction (PCR) analysis of high risk HPV types
(16, 18, 31, 33, 35, 45, 51, 52, 56, 58) using consensus PCR (Ting
and Manos, 1990) and the SHARP detection system (Digene Corp.
(PCR/SHARP). A second sample was then obtained and placed in a
standard sample transport medium to evaluate a simpler signal-
amplified HPV test (Hybrid Capture, Digene Corp.). In the first
half of the study this sample was collected with a dacron swab and
analysed by the Hybrid Capture Tube assay (HC-I), which had a
sensitivity of approximately 10 pg ml–1. In the second half a conical
cervical brush sampling device was used, and the samples were
analysed by the newer Hybrid Capture microtitre format assay
(HC-II). Positivity was evaluated at the conventional 1 pg/ml–1
level as well as higher thresholds of 2 pg ml–1 and 4 pg ml–1.
For the PCR/SHARP assay, PCR amplification was carried out
using consensus primers MY09/11 in a microtitre format and the
presence of high oncogenic risk (HR) HPV types was tested for
using the high-risk probe cocktail as previously described (Terry
et al, 1994). Samples with optical densities more than 0.4 above
background were considered as positive. Samples which were
PCR/SHARP positive were assayed by semi-quantitative type-
specific PCR for HPV16, 18, 31 and 33 (Cuzick et al, 1994).
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Summary Certain types of the human papilloma virus (HPV) are well established as the primary cause of cervical cancer. Several studies
have shown that HPV testing can improve the detection rate of high-grade cervical intraepithelial neoplasia (CIN), but these have been
carried out primarily in younger women. In this study we evaluated the role of HPV testing as an adjunct to cytology in women aged 35 or over.
An additional aim was to evaluate commercially available kits for HPV testing. A total of 2988 eligible women aged 34 or more attending for a
routine smear in 40 general practitioner practices received HPV testing in addition to routine cytology, after having given written informed
consent. Samples were assayed by polymerase chain reaction (PCR) and two versions of the Hybrid Capture test for HPV, and women were
invited for colposcopy if there was any cytological abnormality (including borderline smears) or the PCR test was positive. Any apparent
abnormality was biopsied and loop-excision was performed as necessary. CIN was judged by histology; 42 women had high-grade CIN, of
which six were cytology negative (86% sensitivity for borderline or worse) and three had a borderline smear (79% sensitivity for mild
dyskaryosis or worse). The positive predictive value of a borderline smear was only 3.1%. Eleven high-grade lesions were negative by the
PCR HPV test (sensitivity 74%). The first generation Hybrid Capture II test had a similar sensitivity but an unacceptably high false positive rate
(18.3%), while the newer Hybrid Capture II microtitre kit had a 95% sensitivity and a 2.3% positivity rate in normal women when used at a
2 pg ml–1 cut-off (positive predictive value 27%). Cytology performed very well in this older cohort of women. The newer Hybrid Capture II
microtitre test may be a useful adjunct, especially if the results reported here are reproducible in other studies. A combined screening test
offers the possibility of greater protection and/or longer screening intervals, which could reduce the overall cost of the screening programme.
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Consensus PCR fragments from specimens positive by SHARP
but negative for the four high-risk types by type-specific PCR
were assessed visually by gel electrophoresis and those with band
intensities equivalent to a control amplified in parallel from 10 fg
of HPV 16 DNA were typed for HPV35, 51, 52, 56, 58 by restric-
tion fragment polymorphism analysis as previously described
(Londesborough et al, 1996). In this communication all samples
identified by either of these two methods were scored as positive
for the semi-quantitative HR-HPV assay. Women with a positive
test for HR-HPV by SHARP/PCR or any cytological abnormality
(borderline dyskaryosis or higher) were referred for colposcopy.
Any apparent abnormality was biopsied and treated by loop
excision as necessary. Histology was read independently by two
pathologists who scored the results blindly without reference to
cytological or other clinical information. There were very few
discrepancies and when they did occur the final diagnosis was
determined by consensus opinion.
Statistical methods
The statistical methods used are mostly descriptive. The main
results are presented by two-way contingency tables comparing
cytology and HPV testing to the gold standard of histology.
Relative sensitivity and specificity are determined by comparing
the cases detected by each test to those positive for either test, but
a few positives may have been missed if they were negative on
both tests and thus were not referred for colposcopy. Positive
predictive values are also compared. Referral for colposcopy was
based on cytology and the Consensus PCR/SHARP assay. To
evaluate the Hybrid Capture assay, all patients referred for
colposcopy and a sample of negative controls were evaluated.
Adjustments to the positivity rate were made to compensate for
this sampling procedure. Trends of HPV positivity with age were
evaluated by linear and quadratic logistic regression.
RESULTS
A total of 3103 women were entered into the study. On review, 56
were found to be under the age of 35. Of these, 29 were aged 34
and were therefore included, but the 27 who were under the age of
34 were excluded. Another 20 were excluded because of previous
treatment (15) or cytologic abnormality in the previous 3 years
(five), and 68 were excluded because their cytology slide (19) or
HPV sample (49) was damaged in transit. This left 2988 evaluable
patients. The mean age was 46.0 years and the age distribution is
shown in Figure 1. Some degree of dyskaryosis or glandular
abnormality was found in 70 women (2.4%) and in another 96
cases (3.2%) borderline changes were reported (Table 1).
Forty-two (1.4%) women had high-grade CIN on histology
(CIN2 = eight, CIN3 = 33, adeno-in-situ = one). The sensitivity of
cytology for high-grade CIN was 62% for moderate or severe
dyskaryosis, or glandular atypia, 79% for any dyskaryosis and
86% when also including borderline changes (Table 1). The
positive predictive value (PPV) was 63% for moderate/severe
dyskaryosis, or glandular neoplasia, 24% for mild dyskaryosis and
3% for borderline changes. Overall, the PPV for mild dyskaryosis
or worse was 47%, and for borderline or worse 22%.
Five per cent of smears were judged inadequate. All but eight of
these were HPV-negative and no abnormalities were discovered as
a result of repeat cytology. Eight patients with inadequate smears
were HPV-positive. One of these patients developed a CIN3 lesion
not seen at the initial colposcopy, but diagnosed 17 months later;
the others were negative. The patient with CIN3 had a positive
Hybrid Capture II Microtitre test and positive repeat PCR HPV
test, but repeat cytology was negative.
Six per cent of the samples were HR-HPV-positive by the
PCR/SHARP assay. Figure 2 shows that the rates were highest in
the 35–39 age range and reached a nadir in the 45–49 age group,
but increased again in the older age groups. A logistic regression
with a linear and quadratic age term indicated that the variation
was significant (c2 = 7.00, 2 df, P = 0.03). The positivity rates in
women without any histological evidence of abnormality was
Table 1 Cytology vs histology
Histology
Cytology Inadequate Negative/ HPV/ CIN 1 CIN 2 CIN 3 Adeno in Total
no biopsy borderline situ
Inadequate 0 147 2 0 0 0 0 149 (5.0%)
Negative 3 2636 19 9 1 5 0 2673 (89.4%)
Borderline 4 59 23 7 1 2 0 96 (3.2%)
Mild 0 10 8 4 4 3 0 29 (1.0%)
Moderate 0 2 4 3 0 2 0 11 (0.4%)
Severe 0 1 0 3 1 21 0 26 (0.9%)
Glandular atypia 0 0 1 1 1 0 1 4 (0.1%)
Total 7 2855 57 27 8 33 1 2988 (100%)
(0.2%) (95.6%) (1.9%) (0.9%) (0.3%) (1.1%) (0.03%)
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3.4% (97/2876) and there was a slight increase with age, but this
was not significant (P = 0.32, linear fit) (Figure 2). The sensitivity
for CIN 3/adeno-in-situ was 79.4% and for all high-grade lesions
73.8%. The PPV of the PCR/SHARP test for high-grade CIN was
17.4%. Eleven high-grade lesions were negative for HPV and six
were negative on cytology. Another ten only had borderline (three)
or mild (seven) cytological abnormalities. The specificity and PPV
test was improved when PCR/SHARP-positive samples were
tested semi-quantitatively by type-specific HR-HPV, but at some
loss of sensitivity (Table 2). Four high-grade lesions (two CIN2
and two CIN3) were counted as negative and this reduced the
sensitivity from 74% to 64%. One hundred and six women who
were PCR/SHARP-positive with less than CIN2/3 were found to
have only low levels of HR-HPV and the PPV was improved
substantially to 40% (27/67). Comparative results are shown in
Table 3. This approach most closely parallels the approach taken in
our previous work using type-specific PCR for HPV 16, 18, 31 and
33 (Cuzick et al, 1995), except that we have also added five other
high-risk types (HPV 35, 51, 52, 56, 58). Of these, type 58 appears
(on small numbers) to be most informative here as elsewhere
(Huang et al, 1997). However, as before, types 16 and 31 were the
most common and informative, both with PPVs above 50%.
The Hybrid Capture Test was evaluated restrospectively. For the
first 1285 women, the Hybrid Capture Tube test (HC-I) was used
10
5
0
34–39 40–44 45–49 50–54 55–59 60–64
Age
P
e
r
 
c
e
n
t
All women Women with negative histology or no biopsy
Figure 2 HPV Positivity (SHARP PCR Assay) by age
Table 2 Results of HR-HPV typing in PCR/SHARP-positive samples
Histology
HPV type Inadequate Negative/ Borderline/ CIN 2 CIN 3 Adeno in situ Total
no biopsy CIN 1
16 0 3 6 2 9 1 21
18 0 1 0 1 3 0 5
31 0 3 5 1 9 0 18
33 0 1 1 0 0 0 2
35 0 2 0 0 0 0 2
51 1 1 1 0 0 0 3
52 1 1 6 0 0 0 8
56 0 0 2 0 1 0 3
58 0 2 1 0 3 0 6
Other 0 5 2 0 0 0 7
Neg type 2 75 29 2 2 0 110
Totala 3 93 50 4 26 1 177
Multi-types: HPV16 + 56, CIN3; HPV31 + 52, Bord/HPV; HPV16 + 52, no biopsy; HPV16 + 31, CIN1; HPV51 + 52, Inadequate; HPV11 + 40, Bord/HPV;
HPV16 + 18 + 31, CIN2. aMultiple types counted more than once except in total.HPV testing in primary screening of older women 557
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with a dacron swab for sample collection, whilst in the remaining
1703 patients the Hybrid Capture Microtitre format test (HC-II)
was used with a conical cervical sampler brush. All cases (292)
with non-negative cytology (166) or positive HR-HPV by
PCR/SHARP (177) were assayed, except for six missing samples
(three SHARP-positive, five cytology-positive, four of which were
damaged in transit to the USA). A sample of completely negative
controls was also assayed (62 for HC-I, 330 for HC-II).
Adjustments were made for this sampling scheme.
The initial HC-I tests (carried out in 1995) had good sensitivity
(87.5%), but the false positivity rate was unacceptably high
(18.3%). More recently, we evaluated an additional 170
PCR/SHARP-negative samples by an improved HC-I test and
found that there were only three false positives (1.8%). Two high-
grade lesions (one CIN2, one CIN3) were both positive.
Additional positive samples were not available to adequately
re-evaluate sensitivity. The signal to noise ratio (S/N) for the
10 pg ml–1 positive control in this improved HC-I assay was
6 compared to a S/N of 2 previously.
The HC-II microtitre test performed substantially better than the
HC-I tube test. At the specified 1 pg ml–1 cut-off the microtitre test
had a 100% sensitivity for CIN3 and a 95.2% sensitivity for all
high-grade lesions (20/21). The positivity rate in women with no
evidence of CIN was reduced to 4.9%. In fact, all HPV-positive
cases of CIN 2/3 had levels above 4 pg ml–1, and if a higher cut-off
threshold was used, a lower false positive rate was achieved (2.3%
at 2 pg ml–1, 2.1% at 4 pg ml–1) without any loss of sensitivity.
Since not all of the HC positives were colposcoped, some ‘false
positives’ may be true positives, which would improve the speci-
ficity and PPV. Only two-thirds of the ‘false positive’ results for
HC-II received colposcopy. At either of these thresholds the HC-II
test had a better sensitivity and a better specificity than the HC-I
test, the PCR/SHARP test, or cytology if borderline lesions are
considered positive. The PPV for HC-II was 17%, 27% and 28%,
at the 1, 2 and 4 pg ml–1 cut-offs respectively.
The cytological diagnosis of the 11 PCR/SHARP-negative
women with high-grade CIN showed five with high-grade
cytology, four with mild dyskaryosis and two with borderline
smears. Of these 11, ten had samples available for testing by HC-II
and all of these were positive at above the 4 pg ml–1 level.
DISCUSSION
In this study the PCR/SHARP assay had a sensitivity similar to
that of cytology but a lower specificity in predicting high-grade
lesions. This is not unexpected since we showed previously that
the identification of incident high-grade lesions is dependent on
both the viral types (HR-HPV as detected by PCR/SHARP) and
viral load (not measurable by PCR/SHARP). This is clearly shown
when the PCR/SHARP-positive samples were further tested by
semi-quantitative HR-HPV assay. All but three of the HPV-
positive high-grade lesions were associated with types 16, 18, 31,
or 33, which were the only types tested for in our previous study.
The remaining three cases were all positive for HPV 58,
suggesting this type should also be assayed in screening tests.
Overall, adding the PCR/SHARP assay to any abnormal
cytology increased the yield of high-grade lesions by 17% from 36
to 42. This is substantially less than the 78% found in our previous
study of young women (Cuzick et al, 1995). There are two
possible explanations for this – either cytology performed substan-
tially better and detected more of the high-grade lesions, or the
HPV test performed worse, in that it failed to detect as many of the
high-grade lesions missed by cytology. Since women who were
negative on both tests were not referred for colposcopy, it is
impossible to know for sure which of these is true. However, the
very high correlation of high-grade cytology with high-grade
histology suggests it may have been the former. The sensitivity of
moderate or severe dyskaryosis for CIN 2/3 of 62% is well above
that reported in the literature (Soutter et al, 1986; Walker et al,
1986; Hirschowitz et al, 1992; Jones et al, 1992) where typically
more than half of high-grade lesions initially present with low-
grade or borderline cytology (Kinney et al, 1998).
If HPV testing is to be used as an adjunct to cytology, it is
important that the added sensitivity is achieved without greatly
increasing the referral rate for colposcopy. Only persistent HPV
infection is associated with high-grade CIN, and it may be
appropriate to require two positive HPV tests 6 months apart
before referring patients with negative cytology. Alternatively,
specific predictors of persistence, such as high viral load, age, or
HPV 16 may be adequate risk factors to justify referral after a
single test.
Table 3 Positivity rate (%) by histology for cytology and different HPV tests
Histology
Assay Negative/ Borderline/ High grade CIN 3 + Total PPV for
no biopsy CIN 1 (n = 84) (n = 42) (n = 34) Positive high grade
Cytology: moderate/severe 0.1 14.3 61.9 70.6 1.4 63.4
Cytology: mild or worse 0.5 28.6 78.6 79.4 2.3 47.1
Cytology: borderline or worse 2.5 64.3 85.7 85.3 5.6 21.7
SHARP (n = 2988) 3.4 59.5 73.8 79.4 5.9 17.5
Type specific 0.5 25.0 64.3 73.5 2.0 40.3
Hybrid Capture (Tubes) 18.3a 48.4 (n = 31) 70.4 (n  = 16) 87.5 (n  = 16)  19.9a 4.4a
(n = 1285, but sampled)
Hybrid Capture Microtitre (1 pg) 4.9a 42.1 (n = 38) 95.2 (n = 21) 100 (n = 15) 6.8a 17.1a
(n = 1703, but sampled)
Hybrid Capture Microtitre (2 pg) 2.3a 39.5 95.2 100 4.2a 27.0a
Hybrid Capture Microtitre (4 pg) 2.1a 39.5 95.2 100 4.1a 28.1a
aPercentages adjusted for sampling scheme558 J Cuzick et al
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Only three of the 96 women with borderline cytology had a
high-grade CIN lesion and HPV testing may have a role in the
triage of these women. One of these three was positive for HPV by
PCR/SHARP, but all three were positive by Hybrid Capture. The
PCR/SHARP-positive case also tested positive by HC-I, had HPV
31 and was found to have CIN3. The two PCR/SHARP-negative
cases were both positive by HC-II (one CIN3, one CIN2).
A second objective was to evaluate the Hybrid Capture HPV
test. This was done retrospectively by testing all women who
were either PCR/SHARP- or cytology-positive (referred for
colposcopy), and a sample of controls who were negative on both
tests. Since none of the latter were referred for colposcopy it is
possible that a few more cases might have been detected by the
Hybrid Capture test. Evaluation was complicated by the fact that
the Hybrid Capture test and collection device were changed in the
middle of the study. The older prototype HC-I test had a slightly
better sensitivity than the PCR/SHARP test, but a very poor speci-
ficity, leading to a 18% false positive rate, which is unacceptably
high for a screening test. However, the new HC-II assay, which
was used for about 60% of the study population, performed
substantially better, with a sensitivity in excess of 95%, a false
positive rate of 4.9% when used at the recommended cut-off level
of 1 pg ml–1. In this study, all the positive high-grade lesions had a
value in excess of 4 pg ml–1, and if a 2 pg ml–1 cut-off was used,
there was no loss of sensitivity and the false positive rate was
reduced to 2.3%.
In summary, HPV testing for high-risk types may be a useful
adjunct to cytology, especially if a quantitative assay is used. The
new Hybrid Capture test (HC-II) is a strong candidate if the results
reported here are reproducible. The detection rate of HC-II was
better than cytology for high-grade CIN and the subjective evalua-
tion and difficult borderline category is avoided. This higher
sensitivity could lead to cost savings if it allows the screening
interval to be safely lengthened and would more than compensate
for the cost of the test (Cuzick and Sasieni, 1997). Another area
where HPV testing may improve screening outcomes and save
costs is for borderline smears. This could be achieved by referring
HR-HPV-positive cases immediately and reducing surveillance in
those who are HR-HPV-negative. However, a major concern for
any screening test is the false positive rate. This was only 2.3% for
HC-II when a higher cut-off point was used to determine posi-
tivity, and it may be possible to reduce this further by requiring a
repeat HPV test when cytology is negative but HPV is positive.
The role of HPV typing in management strategies requires further
investigation.
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